Silence Therapeutics plc (SLN) Earnings History
Net Loss31 years of earnings data (1995–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Silence Therapeutics plc (SLN) Earnings Overview
As of June 30, 2026, Silence Therapeutics plc (SLN) reported trailing twelve-month net income of -$75M, reflecting +20.3% year-over-year growth. The company earned $-1.59 per diluted share over the past four quarters, with a net profit margin of -15851.9%.
Looking at the long-term picture, SLN's historical earnings data spans multiple years. The company achieved its highest annual net income of -$874,000 in fiscal 1995.
Silence Therapeutics plc is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ALNY ($577M net income, 8.4% margin), ARWR (-$301M net income, -0.2% margin), SRPT ($65M net income, -32.5% margin), SLN has room to improve margins relative to the peer group. Compare SLN vs ALNY →
SLN Earnings vs Peers
Earnings metrics vs comparable public companies
SLN Historical Earnings Data (1995–2025)
31 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$89M | -95.6% | -$90M | $-1.89 | -15851.9% | -16056.0% |
| 2024 | -$45M | -4.7% | -$63M | $-2.37 | -104.7% | -146.4% |
| 2023 | -$43M | -5.4% | -$50M | $-3.48 | -170.5% | -195.5% |
| 2022 | -$41M | -4.1% | -$50M | $-3.78 | -232.4% | -281.9% |
| 2021 | -$39M | -21.1% | -$46M | $-1.35 | -317.4% | -369.0% |
| 2020 | -$33M | -66.2% | -$36M | $-1.11 | -594.0% | -654.3% |
| 2019 | -$20M | -6.4% | -$23M | $-0.78 | -8025.4% | -9317.2% |
| 2018 | -$18M | -1037.9% | -$21M | $-0.83 | - | - |
| 2017 | -$2M | +80.8% | -$14M | $-0.07 | -10112.5% | -89943.8% |
| 2016 | -$8M | -27.0% | -$12M | $-0.40 | -1096.1% | -1546.2% |
| 2015 | -$7M | +40.1% | -$10M | $-0.32 | - | - |
| 2014 | -$11M | -23.2% | -$12M | $-0.68 | -73920.0% | -80846.7% |
| 2013 | -$9M | +65.8% | -$9M | $-0.58 | -7694.0% | -7753.8% |
| 2012 | -$26M | -358.1% | -$26M | $-3.99 | -16125.2% | -16143.6% |
| 2011 | -$6M | +34.8% | -$6M | $-1.75 | -826.7% | -833.7% |
| 2010 | -$9M | -17.7% | -$9M | $-4.20 | -371.7% | -365.9% |
| 2009 | -$7M | -0.5% | -$8M | $-7.23 | -433.6% | -438.4% |
| 2008 | -$7M | -45.6% | -$8M | $-8.73 | -336.6% | -352.7% |
| 2007 | -$5M | -33.5% | -$6M | $-5.91 | -126.2% | -143.0% |
| 2006 | -$4M | -6.7% | -$4M | $-5.19 | -196.5% | -219.2% |
| 2005 | -$4M | -21.3% | -$4M | $-8.28 | -704.3% | -765.8% |
| 2004 | -$3M | -29.6% | -$3M | $-15.75 | -1859.1% | -2118.2% |
| 2003 | -$2M | -53.7% | -$3M | $-14.34 | -169.6% | -198.9% |
| 2002 | -$1M | +32.4% | -$2M | $-9.33 | -128.8% | -174.2% |
| 2001 | -$2M | -12.9% | -$3M | $-13.80 | -1589.9% | -2193.5% |
| 2000 | -$2M | +9.2% | -$3M | $-12.78 | -202.7% | -285.2% |
| 1999 | -$2M | -35.5% | -$2M | $-15.60 | -156.2% | -159.1% |
| 1998 | -$2M | +10.3% | -$2M | $-12.00 | -751.9% | -906.2% |
| 1997 | -$2M | -82.5% | -$2M | $-13.68 | - | - |
| 1996 | $-965,000 | -10.4% | -$1M | $-7.59 | - | - |
| 1995 | $-874,000 | - | $-933,000 | $-7.95 | - | - |
Download Data
Export SLN earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
31+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
SLN — Frequently Asked Questions
Quick answers to the most common questions about buying SLN stock.
What is SLN earnings per share (EPS)?
SLN trailing twelve-month (TTM) diluted EPS is $-1.59, reflecting +20.3% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 1995 to 2025 is available in the table on this page.
What is Silence Therapeutics plc's net income?
Silence Therapeutics plc (SLN) trailing twelve-month net income is $-75M as of 2025. Earnings grew +20.3% year-over-year.
Is SLN profitable?
SLN is not currently profitable on a TTM basis, reporting a net loss of $-75M. Net margin is -15851.9%. Investors should monitor for a return to profitability.
What is SLN's earnings growth rate?
SLN compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 1995 to 2025.
What are SLN's profit margins?
Silence Therapeutics plc net profit margin is -15851.9%, operating margin is -16056.0%, and gross margin is +61.5%. Below-average margins reflect competitive or cost pressures. Return on Equity is -90.3%.
Is SLN growing earnings?
Yes, SLN earnings are accelerating — EPS growth of +20.3% exceeds the 5-year CAGR of N/A. TTM net income reached $-75M. Earnings momentum is strengthening.
What was SLN's best earnings year?
Silence Therapeutics plc's highest annual net income on record is $-874000.00, achieved in fiscal year 1995. Earnings history on this page spans 1995 to 2025 and includes all annual and quarterly figures.
What were SLN's earnings last quarter?
SLN's most recent reported quarter was Q1 2026. Net income was $-15M with diluted EPS of $-0.33. For a full breakdown of all quarters, see the quarterly earnings table on this page.